14.75
0.89%
0.1273
Acadia Pharmaceuticals Inc stock is traded at $14.75, with a volume of 849.96K.
It is up +0.89% in the last 24 hours and down -2.32% over the past month.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
See More
Previous Close:
$14.62
Open:
$14.745
24h Volume:
849.96K
Relative Volume:
0.59
Market Cap:
$2.43B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
-16.03
EPS:
-0.92
Net Cash Flow:
$80.53M
1W Performance:
+0.07%
1M Performance:
-2.32%
6M Performance:
-13.49%
1Y Performance:
-38.72%
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
Mar-12-24 | Reiterated | Needham | Buy |
Jan-30-24 | Initiated | Robert W. Baird | Outperform |
Jan-24-24 | Upgrade | Needham | Hold → Buy |
Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
Dec-13-23 | Initiated | Citigroup | Buy |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
Oct-17-23 | Initiated | UBS | Buy |
Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
Nov-01-22 | Initiated | Loop Capital | Hold |
Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-23-21 | Resumed | Needham | Hold |
Jun-10-21 | Initiated | Berenberg | Hold |
Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
Mar-09-21 | Downgrade | Stifel | Buy → Hold |
Dec-16-20 | Initiated | Mizuho | Buy |
Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
Aug-25-20 | Initiated | Raymond James | Outperform |
Aug-20-20 | Initiated | Morgan Stanley | Overweight |
Jul-07-20 | Upgrade | Stifel | Hold → Buy |
Apr-16-20 | Initiated | Jefferies | Buy |
Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
Mar-06-20 | Initiated | Citigroup | Buy |
Dec-16-19 | Initiated | Guggenheim | Buy |
Oct-24-19 | Initiated | Oppenheimer | Perform |
Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
Jul-23-19 | Reiterated | Needham | Buy |
Dec-10-18 | Initiated | Canaccord Genuity | Hold |
Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
Aug-09-18 | Reiterated | Stifel | Hold |
Aug-07-18 | Initiated | Stifel | Hold |
Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by AlphaCentric Advisors LLC - MarketBeat
ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024 - Insider Monkey
10 Worst-Performing Growth Stocks in 2024 - Insider Monkey
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
ACADIA Pharmaceuticals (ACAD) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Emerging Insights: Market Trends in Multiple System Atrophy (MSA) Market | Acadia Pharmaceuticals Inc - EIN News
ACADIA Pharmaceuticals' SWOT analysis: stock outlook mixed as DAYBUE uptake lags By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals' SWOT analysis: stock outlook mixed as DAYBUE uptake lags - Investing.com India
ACADIA Pharmaceuticals stock hits 52-week low at $14.31 By Investing.com - Investing.com Australia
ACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 1-Year LowWhat's Next? - MarketBeat
ACADIA Pharmaceuticals stock hits 52-week low at $14.31 - Investing.com India
Parkinsons Disease Psychosis Market Forecasted to Surge - openPR
Ryan Reynolds' Latest Film: 'More To Parkinson's' 08/19/2024 - MediaPost Communications
(ACAD) Long Term Investment Analysis - Stock Traders Daily
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Acadia's DAYBUE wins first Canada nod for Rett syndrome treatment By Investing.com - Investing.com Australia
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 - BioSpace
Equities Analysts Issue Forecasts for ACADIA Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ACAD) - MarketBeat
Health Canada approves Acadia’s DAYBUE for Rett syndrome - Pharmaceutical Technology
Acadia's DAYBUE wins first Canada nod for Rett syndrome treatment - Investing.com
Neuren announces that trofinetide has received marketing authorisation in Canada - Biotech Dispatch
Acadia Pharmaceuticals Announces Health Canada Approval Of DAYBUE (Trofinetide) For The Treatment Of Rett Syndrome - XM
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome - StockTitan
Parkinsons Disease Therapeutics Market to Grow with Incredible - openPR
Are ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? - Yahoo Finance
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Down 13.5% in September - MarketBeat
Zacks Research Research Analysts Lift Earnings Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Autism Spectrum Disorder Market, 2034 | Scioto Biosciences, - openPR
ACADIA Pharmaceuticals (NASDAQ:ACAD) Receives "Market Perform" Rating from Raymond James - MarketBeat
Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know - Benzinga
Sanctuary Advisors LLC Acquires Shares of 91,834 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Long Term Trading Analysis for (ACAD) - Stock Traders Daily
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year LowHere's What Happened - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Simply Wall St
Healthcare of Ontario Pension Plan Trust Fund Decreases Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Inside Ryan Reynolds’ heartfelt Parkinson’s campaign - PR Week
Dimensional Fund Advisors LP Buys Shares of 649,150 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
SG Americas Securities LLC Buys 417,648 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
The Manufacturers Life Insurance Company Reduces Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Schizophrenia Market Projected for Significant Growth by 2034: - openPR
Glioblastoma Pipeline Trends 2024: Clinical Trials, - openPR
Millennium Management LLC Has $47.74 Million Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Schizophrenia Market Forecasted to Surge in Coming Years, - openPR
Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Update - MarketBeat
Algert Global LLC Buys 179,799 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia replaces outgoing CEO with BMS exec - The Pharma Letter
How to Take Advantage of moves in (ACAD) - Stock Traders Daily
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Acquired by D. E. Shaw & Co. Inc. - MarketBeat
Acadia Pharmaceuticals surges 32% after win in patent suit over Nuplazid (update) - MSN
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):